Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 4,172 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Completed Early Phase 1 Interventional

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

NCT02420977
View directory record Official record
Conditions
Advanced Prostate Cancer
Interventions
Pelvic DCFPyL PET-MRI fusion or PET/MRI
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

NCT04288687
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Niraparib Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Active, not recruiting Phase 2 Interventional

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

NCT03181867
View directory record Official record
Conditions
Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
Interventions
18F-DCFPyL, 18F-FDG, PSMA-11
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Recruiting Phase 1 Interventional

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

NCT05398302
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Image Guided Biopsy
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

NCT05800665
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer
Interventions
RO7656594
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Recruiting Not applicable Interventional

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

NCT04693377
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Prostate Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcoma, Metastatic Thyroid Gland Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Results available

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

NCT03840200
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Ovarian Cancer
Interventions
Ipatasertib, Rucaparib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Marcos, California • East Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

NCT00348595
View directory record Official record
Conditions
Prostate Cancer
Interventions
Revlimid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

NCT01327495
View directory record Official record
Conditions
Healthy
Interventions
placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 30, 2026, 2:17 AM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer

NCT00045331
View directory record Official record
Conditions
Prostate Cancer
Interventions
proteomic profiling
Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 30, 2026, 2:17 AM EDT
Withdrawn Phase 2 Interventional

Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy

NCT00003622
View directory record Official record
Conditions
Prostate Cancer
Interventions
paclitaxel, vinorelbine tartrate
Drug
Lead sponsor
James Ahlgren
Other
Eligibility
18 Years to 120 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Hormone Refractory Prostate Cancer

NCT00105053
View directory record Official record
Conditions
Prostate Cancer
Interventions
HyperAcute-Prostate Cancer Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
19 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Phase 3 Interventional

The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis

NCT00171639
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Tucson, Arizona • Long Beach, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 30, 2026, 2:17 AM EDT
Completed No phase listed Observational

Changes in DNA After Radiation Therapy in Patients With Prostate Cancer

NCT00899912
View directory record Official record
Conditions
Prostate Cancer
Interventions
microarray analysis, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Atlanta, Georgia • Springfield, Illinois • City of Saint Peters, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer

NCT03397030
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Home-Based Exercise Program
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
40 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 30, 2026, 2:17 AM EDT
Active, not recruiting Phase 2 Interventional

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

NCT03902951
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Recruiting No phase listed Observational

Longitudinal Advanced Prostate Cancer Cohort (LAPCC)

NCT06067295
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

NCT02312401
View directory record Official record
Conditions
Prostate Cancer
Interventions
multi-parametric MRI(MP-MRI), dynamic contrast-enhanced MRI (DCE), biopsy
Device · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer

NCT01338012
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Laguna Hills, California • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 30, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

Doxercalciferol Before Surgery in Treating Localized Prostate Cancer

NCT00022412
View directory record Official record
Conditions
Prostate Cancer
Interventions
doxercalciferol, conventional surgery
Dietary Supplement · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 120 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
6
States / cities
Iowa City, Iowa • Rochester, New York • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 30, 2026, 2:17 AM EDT
Withdrawn Phase 4 Interventional

Role of Prophylactic Postoperative Antibiotics in HoLEP

NCT05274672
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Urinary Tract Infections
Interventions
Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination, Ciprofloxacin, Holmium Laser Enucleation of prostate
Drug · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

NCT04788277
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
50 Years to 79 Years · Male only
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 2:17 AM EDT
Not listed Not applicable Interventional Results available

Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites

NCT04267575
View directory record Official record
Conditions
Recurrent Malignant Solid Neoplasm, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IV Pancreatic Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Liver Cancer, Stage IV Renal Cell Cancer, Stage IV Rectal Cancer, Stage IV Lung Cancer, Stage IV Small Intestinal Cancer, Stage IV Gastric Cancer, Stage IV Bladder Cancer
Interventions
Canady Helios Cold Plasma Scalpel
Device
Lead sponsor
Jerome Canady, M.D.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 30, 2026, 2:17 AM EDT